Table of Contents
- Trial overview
- Who can participate
- Study design and treatment groups
- What is being measured
- Trial status and size
Trial overview
One clinical trial is studying NBI-1117570 in adults with schizophrenia who need inpatient hospitalization.[1] The trial is designed to see whether the study drug can improve behavioral and psychological symptoms of schizophrenia compared with placebo.[1]
This is an interventional study, which means researchers give a study treatment and then measure the results.[1] The trial is in Phase 2, so it is focused on learning more about how well the treatment may work while still collecting study information on safety and effects.[1]
Who can participate
The trial is for inpatient adults with schizophrenia.[1] Inpatient means the person is staying in a hospital setting for treatment, not just coming for a short visit.[1]
The source data does not give more detail about other entry rules, such as exact age limits, symptom levels, or past treatment history.[1]
Study design and treatment groups
The trial compares NBI-1117570 with placebo.[1] A placebo is a look-alike treatment that does not contain the active study drug, and it helps researchers compare outcomes in a fair way.[1]
The intervention list shows oral use for NBI-1117570 and a placebo for NBI-1117570.[1] The study data do not provide more detail about the schedule of treatment or how long participants are followed.[1]
What is being measured
The main outcome is the change from baseline in the Positive and Negative Syndrome Scale, or PANSS, total score.[1] Baseline means the starting measurement before treatment begins.[1]
PANSS is a score used to measure how severe schizophrenia symptoms are.[1] In simple terms, the researchers are checking whether symptoms improve after treatment and whether the change is greater than with placebo.[1]
Trial status and size
The trial status is Authorised, which means it has permission to start.[1] The planned enrollment is 169 participants.[1]
Because only one trial is listed in the source data, the current research picture for NBI-1117570 is limited to this Phase 2 study in hospitalized adults with schizophrenia.[1]
